Cariprazine hydrochloride

Management to Participate in 8th Annual Evercore Annual Healthcare ConferenceNESS ZIONA, Israel, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 8th Annual Evercore Annual Healthcare Conference, to take place December 2-4, 2025, in Miami, Florida. Mapi is actively seeking additional partnerships for its new proprietary Depot products. Company management will be available for one-on-one meetings during the Annual Evercore Annual Healthcare Conference to discuss potential joint development collaborations. Interested parties should contact Mapi directly or their representative at Evercore to arrange a meeting. Mapi utilizes extended-release Depot technologies with strong IP to develop Lifecycle Management products for innovative and existing commercially successful pharmaceuticals across multiple therapeutic areas. The Company currently has one product which is fully under a commercialization agreement, GA Depot for Relapsing Forms of Multiple Sclerosis (RMS) and other products for diabetes and schizophrenia which are funded through Phase II results. The development pipeline also includes an injectable version of cariprazine, developed using Mapi’s Depot technology, which has demonstrated a long-acting release profile, for one monthly injection. It is designed to address an unmet need in the treatment of schizophrenia, bipolar I and major depression disorders. Mapi recently began enrolling patients in a Phase I/II study. Mapi is fully integrated in the development of Depot pharmaceuticals and offers partners multiple distinct technologies. The Company has an extensive R&D team with dedicated Depot labs, experienced clinical team, as well as a large-scale, state-of-the-art GMP approved manufacturing facility for both clinical development and commercial supply. Mapi has the capabilities to efficiently develop Depot products by integrating R&D, clinical studies, registration and manufacturing with a successful track record of improving time to market. Ehud Marom, Chairman and Chief Executive Officer, Mapi Pharma, said, “We have a number of compelling partnering opportunities in our current pipeline, including Deutetrabenazine (AUSTEDO® XR) Depot for the treatment of Huntington's disease and tardive dyskinesia, and Anastrazole (Arimidex®) Depot as an adjuvant treatment for postmenopausal women with hormone receptor-positive early breast cancer as well as other candidates. We can also apply our technologies to co-develop Depot drugs with companies that are interested in developing long-acting injectable lifecycle management versions of their molecules." About Mapi PharmaMapi Pharma (Mapi) is a clinical stage pharmaceutical company, engaged in development of high barrier-to-entry and high added-value life cycle management ("LCM") products and AB Rated Depot injectable products that target large markets that include complex active pharmaceutical ingredients ("APIs") and formulations. Mapi’s lead product is GA Depot which is partnered with Viatris (NASDAQ: VTRS) in an agreement under which Viatris was granted an exclusive license to commercialize the GA Depot injection product for Relapsing Forms of Multiple Sclerosis (RMS). Following successful Phase 3 results GA Depot is currently under FDA review. The Company is also marketing its own generic versions of Fingolimod (Gilenya®) and Apremilast (Otezla®) in specific geographic markets. Mapi's portfolio also includes a leading development of Depot drugs for Schizophrenia, GLP-1 for diabetes, weight loss, with innovative intellectual property. Mapi is built on strong chemical and pharmaceutical R&D and clinical development capabilities and a deep understanding of the global market and of regulatory needs. Mapi is a global company with an API production and aseptic Depot manufacturing and a Fill & Finish for injectable Finished Dosage Forms facilities. Mapi has strong IP positions, filing numerous patent applications for APIs and formulations. For more information, please visit www.mapi-pharma.com Contacts:Alex MogleVice President, Corporate DevelopmentMapi Pharma+972 52 6080297alex@mapi-pharma.com Brian RitchieManaging DirectorLifeSci Advisors, LLCbritchie@lifesciadvisors.com

London: U.S. Medicare price cuts of up to 85% will have a lesser impact on drugmakers than initially feared, with most of the hit already reflected in forecasts, Wall Street analysts said. Shares of Danish drugmaker Novo Nordisk and Teva Pharmaceuticals rose 5% and 3% respectively after the U.S. government published negotiated prices late on Tuesday. Novo's top-selling drug semaglutide, sold as Ozempic for diabetes and Wegovy for weight loss, as well as Teva's Austedo for Hungtington disease were among the closely watched drugs on the list of prices, which will take effect in 2027. The announcement and recent White House deals offer clarity on pricing for popular GLP-1 drugs such as Wegovy and Eli Lilly's Zepbound, which have drawn scrutiny over their costs. The negotiated price for Novo's semaglutide is "the final cloud to clear on the drawn-out, but positively resolved GLP-1 pricing debate ," said Bernstein analyst Christian Moore. The price cuts through the U.S. Medicare health plan come as President Donald Trump's administration pushes the drug industry to advocate for other wealthy nations, particularly in Europe, to pay more for prescription medicines. Goldman Sachs said a key question for the first half of 2026 will be whether lower Medicare prices boost Wegovy volumes. William Blair analysts noted the $274 monthly price for Novo's semaglutide broadly aligns with recent government deals, but said uncertainty remains over insurance coverage expansion. FACTORED INTO NOVO, ASTRAZENECA AND GSK FORECASTS Bernstein analysts said that five of the 15 targeted medicines will become generic by 2027, limiting their exposure to price cuts. The lower prices could even keep patients on the branded therapies longer, boosting volumes, they said. Analysts agreed that the reductions had been factored into estimates for Novo, AstraZeneca and GSK. Earlier this month, Novo said it expected a low single-digit impact to global sales if the price cuts were implemented this year. Analysts said that would imply roughly a 6 billion Danish crown ($931 million) sales hit. AstraZeneca and GSK shares were flat on Wednesday. GSK said when reporting third-quarter results that any impact from negotiated prices was fully factored into its outlook. Shore Capital analyst Sean Conroy said the cuts would hit earnings by "low- to mid-hundreds" of millions of pounds or dollars. Bernstein estimated the impact on Abbie in the range of $100 million to $250 million to sales of its mood disorder drug Vraylar and irritable bowel syndrome medicine Linzess as well as for Amgen's psoriasis drug Otezla. ($1 = 6.4404 Danish crowns) (Reporting by Bhanvi Satija and Maggie Fick in London, Stine Jacobsen in Copenhagen, Mariam Sunny and Mrinalika Roy in Bengaluru; Editing by Jane Merriman, Jan Harvey and Alexander Smith)